Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Nanus

Showing results (61-70 of 168) with videos related to

Pageof 17
Sort By:
Cancer|November 4, 2006
Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progressionIman Osman, Jie Dai, Maryann Mikhail, et al.
Carcinogenesis|December 14, 2005
Decreased expression of the human stem cell marker, Rex-1 (zfp-42), in renal cell carcinomaJay D Raman, Nigel P Mongan, Limin Liu, et al.
Frontiers in Oncology|December 31, 2021
Mitochondrial Ndufa4l2 Enhances Deposition of Lipids and Expression of Ca9 in the TRACK Model of Early Clear Cell Renal Cell CarcinomaKristian B Laursen, Qiuying Chen, Francesca Khani, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 6, 2005
Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigenShankar Vallabhajosula, Stanley J Goldsmith, Klaus A Hamacher, et al.
Current Radiopharmaceuticals|March 16, 2015
Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal AntibodyShankar Vallabhajosula, Anastasia Nikolopoulou, Yuliya S Jhanwar, et al.
Seminars in Urologic Oncology|September 7, 2002
The utility of monoclonal antibodies in the imaging of prostate cancerDaniel Yao, Edouard J Trabulsi, Lale Kostakoglu, et al.
Molecular Cancer Research : MCR|March 27, 2021
Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate CancerSantosh Gupta, Susan Halabi, Gabor Kemeny, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2009
Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urotheliumMatthew I Milowsky, David M Nanus, Fernando C Maluf, et al.
European Urology|November 22, 2011
Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancerAndrew J Armstrong, Mario A Eisenberger, Susan Halabi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2007
Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumorsMatthew I Milowsky, David M Nanus, Lale Kostakoglu, et al.
Pageof 17

Showing results (61-70 of 168) with videos related to

Sort By:
Pageof 17
Cancer|November 4, 2006
Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progressionIman Osman, Jie Dai, Maryann Mikhail, et al.
Carcinogenesis|December 14, 2005
Decreased expression of the human stem cell marker, Rex-1 (zfp-42), in renal cell carcinomaJay D Raman, Nigel P Mongan, Limin Liu, et al.
Frontiers in Oncology|December 31, 2021
Mitochondrial Ndufa4l2 Enhances Deposition of Lipids and Expression of Ca9 in the TRACK Model of Early Clear Cell Renal Cell CarcinomaKristian B Laursen, Qiuying Chen, Francesca Khani, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 6, 2005
Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigenShankar Vallabhajosula, Stanley J Goldsmith, Klaus A Hamacher, et al.
Current Radiopharmaceuticals|March 16, 2015
Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal AntibodyShankar Vallabhajosula, Anastasia Nikolopoulou, Yuliya S Jhanwar, et al.
Seminars in Urologic Oncology|September 7, 2002
The utility of monoclonal antibodies in the imaging of prostate cancerDaniel Yao, Edouard J Trabulsi, Lale Kostakoglu, et al.
Molecular Cancer Research : MCR|March 27, 2021
Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate CancerSantosh Gupta, Susan Halabi, Gabor Kemeny, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2009
Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urotheliumMatthew I Milowsky, David M Nanus, Fernando C Maluf, et al.
European Urology|November 22, 2011
Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancerAndrew J Armstrong, Mario A Eisenberger, Susan Halabi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2007
Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumorsMatthew I Milowsky, David M Nanus, Lale Kostakoglu, et al.
Pageof 17